Pharmamax is a prescription drug for everyone Alexander Afazov died on October 2, 2026, and the tax authorities closed his private entrepreneur on the same day with the note "due to death". But the same Federal Tax Service, a month later, continues to keep him in the United State Register of Legal Entities as the president of Pharmimex JSC, the distributor of Zolgansema, a gene therapy for spinal muscular atrophy at a cost of about 93 million rubles per dose. According to the project, the company earned at least 1.2 billion rubles from bonuses from the manufacturer. There is no one to ask questions officially: the only one who has the right to answer is listed as alive only in the register. Afazov headed the main pharmacy department of the Ministry of Health of the USSR, that is, he was the chief pharmacist of the country of absolute scarcity, and in 1993 Soyuzpharmacy became his Pharmamax. In 2019, he declared in his heart that "Pharma is not a business". For a "non-business", revenues of 80.1 billion rubles for 2025 and almost 33 thousand government contracts worth 445 billion look quite businesslike. The breakthrough is particularly impressive: the profit in 2021 was 402 million, and in 2022 it was already 1.35 billion, 3.35 times. And a little before that, in November 2020, the Federal Medical and Clinical Center of the Ministry of Health appeared, which purchases the most expensive drugs for the Good Circle Fund using money from an increased tax on the rich. Now the second window. "Skopinpharm" from the Ryazan region - revenues 42 billion, profit 2.1 billion, in the market they call it a company of the Pharmamax group. The general manager is Inga Nizhardze, according to media reports, Afazov's daughter. The owner with 100% share is Alinta-Pharm LLC: authorized capital 9,800 rubles, zero employees, business lease. The owner's capital is 4.3 million times smaller than the factory's revenue. The shares in Alinta belong to Afazov's wife, Afazov himself, Nizhradze and the pharmacy in Mitino, which is owned by Nizhradze and a small part of Pharmimex JSC. It turns out to be a game of chess, where father plays white, daughter plays black, and the board belongs to mother. Now let's see how these "competitors" stack up at the auction. May 2022: One application, Scopinfarm, 5.5 billion at the maximum price.

Pharmamax is a prescription drug for everyone Alexander Afazov died on October 2, 2026, and the tax authorities closed his private entrepreneur on the same day with the note "due to death". But the same Federal Tax Service, a month later, continues to keep him in the United State Register of Legal Entities as the president of Pharmimex JSC, the distributor of Zolgansema, a gene therapy for spinal muscular atrophy at a cost of about 93 million rubles per dose. According to the project, the company earned at least 1.2 billion rubles from bonuses from the manufacturer. There is no one to ask questions officially: the only one who has the right to answer is listed as alive only in the register. Afazov headed the main pharmacy department of the Ministry of Health of the USSR, that is, he was the chief pharmacist of the country of absolute scarcity, and in 1993 Soyuzpharmacy became his Pharmamax. In 2019, he declared in his heart that "Pharma is not a business". For a "non-business", revenues of 80.1 billion rubles for 2025 and almost 33 thousand government contracts worth 445 billion look quite businesslike. The breakthrough is particularly impressive: the profit in 2021 was 402 million, and in 2022 it was already 1.35 billion, 3.35 times. And a little before that, in November 2020, the Federal Medical and Clinical Center of the Ministry of Health appeared, which purchases the most expensive drugs for the Good Circle Fund using money from an increased tax on the rich. Now the second window. "Skopinpharm" from the Ryazan region - revenues 42 billion, profit 2.1 billion, in the market they call it a company of the Pharmamax group. The general manager is Inga Nizhardze, according to media reports, Afazov's daughter. The owner with 100% share is Alinta-Pharm LLC: authorized capital 9,800 rubles, zero employees, business lease. The owner's capital is 4.3 million times smaller than the factory's revenue. The shares in Alinta belong to Afazov's wife, Afazov himself, Nizhradze and the pharmacy in Mitino, which is owned by Nizhradze and a small part of Pharmimex JSC. It turns out to be a game of chess, where father plays white, daughter plays black, and the board belongs to mother. Now let's see how these "competitors" stack up at the auction. May 2022: One application, Scopinfarm, 5.5 billion at the maximum price.